Treatment Clinical Trials for Kaposi Sarcoma

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical trials are research studies that involve people. The clinical trials on this list are for Kaposi sarcoma treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-8 of 8
  • Nivolumab and Ipilimumab in Treating Patients with HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

    This phase I trial studies the side effects and best dose of nivolumab when given with ipilimumab in treating patients with human immunodeficiency virus (HIV) associated classical Hodgkin lymphoma that has returned after a period of improvement or does not respond to treatment, or solid tumors that have spread to other places in the body or cannot be removed by surgery. Monoclonal antibodies, such as ipilimumab and nivolumab, may block tumor growth in different ways by targeting certain cells. Ipilimumab is an antibody that acts against a molecule called cytotoxic T-lymphocyte antigen 4 (CTLA-4). CTLA-4 controls a part of your immune system by shutting it down. Nivolumab is a type of antibody that is specific for human programmed cell death 1 (PD-1), a protein that is responsible for destruction of immune cells. Giving ipilimumab with nivolumab may work better in treating patients with HIV associated classical Hodgkin lymphoma or solid tumors.
    Location: 22 locations

  • Pembrolizumab in Treating Patients with HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms

    This phase I trial studies the side effects of pembrolizumab in treating patients with human immunodeficiency virus (HIV) and malignant neoplasms that have come back (relapsed), do not respond to treatment (refractory), or have distributed over a large area in the body (disseminated). Monoclonal antibodies, such as pembrolizumab, may block tumor or cancer growth in different ways by targeting certain cells. It may also help the immune system kill cancer cells.
    Location: 10 locations

  • EphB4-HSA in Treating Patients with Kaposi Sarcoma

    This phase II trial studies recombinant EphB4-HSA fusion protein (EphB4-HSA) in treating patients with Kaposi sarcoma. Recombinant EphB4-HSA fusion protein may block the growth of blood vessels that provide blood to the cancer, and may also prevent cancer cells from growing.
    Location: 7 locations

  • Nelfinavir Mesylate in Treating Patients with Kaposi Sarcoma

    This pilot phase II trial studies how well nelfinavir mesylate works in treating patients with kaposi sarcoma. Nelfinavir mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 5 locations

  • Natural History of Targeted Antiviral and Cancer Therapy in Treating Patients with KSHV-Associated Multicentric Castleman Disease

    This clinical trial studies the natural history of targeted antiviral and cancer therapy in treating patients with Kaposi’s sarcoma herpes virus (KSHV)-associated multicentric Castleman disease (MCD). Gathering information over time about patients with KHSV-associated MCD receiving antiviral therapy, monoclonal antibody therapy, and combination chemotherapy may help doctors learn more about the disease and find better methods of treatment and on-going care.
    Location: 2 locations

  • Pomalidomide and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients with Advanced or Refractory Kaposi Sarcoma

    This phase I trial studies the side effects and best dose of pomalidomide when given together with pegylated liposomal doxorubicin hydrochloride in treating patients with Kaposi sarcoma that has spread to other places in the body or that does not respond to treatment. Biological therapies, such as pomalidomide, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Drugs used in chemotherapy, such as pegylated liposomal doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pomalidomide and pegylated liposomal doxorubicin hydrochloride may work better in treating patients with Kaposi sarcoma.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Pomalidomide in Treating Patients with Kaposi Sarcoma with or without HIV

    This phase I / II trial studies the side effects of pomalidomide and to see how well it works in treating patients with Kaposi sarcoma with or without human immunodeficiency virus (HIV). Biological therapies, such as pomalidomide, may stimulate the immune system in different ways and stop tumor cells from growing and may also prevent the growth of new blood vessels that tumors need to grow.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Tocilizumab with or without Zidovudine and Valganciclovir in Treating Patients with Kaposi Sarcoma Herpes Virus-Associated Multicentric Castleman Disease

    This pilot phase II trial studies tocilizumab in treating patients with Kaposi sarcoma herpes virus-associated multicentric Castleman disease. Monoclonal antibodies, such as tocilizumab, can block the ability of cancer to grow and spread. Herpes virus is found in the lesions of most patients with Kaposi's sarcoma and may help cause Kaposi's sarcoma. Zidovudine and valganciclovir are antiviral drugs that act against many types of herpes viruses. Giving tocilizumab with zidovudine and valganciclovir may be an effective treatment for Kaposi's sarcoma herpes virus-associated multicentric Castleman disease.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland